Logo image of RKDA

ARCADIA BIOSCIENCES INC (RKDA) Stock Fundamental Analysis

NASDAQ:RKDA - Nasdaq - US0390143032 - Common Stock

4.95  -0.06 (-1.2%)

After market: 5.05 +0.1 (+2.02%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RKDA. RKDA was compared to 91 industry peers in the Food Products industry. While RKDA has a great health rating, there are worries on its profitability. While showing a medium growth rate, RKDA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RKDA had negative earnings in the past year.
In the past year RKDA has reported a negative cash flow from operations.
In the past 5 years RKDA always reported negative net income.
In the past 5 years RKDA always reported negative operating cash flow.
RKDA Yearly Net Income VS EBIT VS OCF VS FCFRKDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

RKDA's Return On Assets of -38.23% is on the low side compared to the rest of the industry. RKDA is outperformed by 83.72% of its industry peers.
RKDA has a worse Return On Equity (-56.64%) than 80.23% of its industry peers.
Industry RankSector Rank
ROA -38.23%
ROE -56.64%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-51.16%
ROE(3y)-76.39%
ROE(5y)-123.93%
ROIC(3y)N/A
ROIC(5y)N/A
RKDA Yearly ROA, ROE, ROICRKDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

With an excellent Gross Margin value of 46.96%, RKDA belongs to the best of the industry, outperforming 97.67% of the companies in the same industry.
In the last couple of years the Gross Margin of RKDA has declined.
RKDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.48%
GM growth 5Y-3.26%
RKDA Yearly Profit, Operating, Gross MarginsRKDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

7

2. Health

2.1 Basic Checks

RKDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RKDA has more shares outstanding
RKDA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RKDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RKDA Yearly Shares OutstandingRKDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
RKDA Yearly Total Debt VS Total AssetsRKDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -25.27, we must say that RKDA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -25.27, RKDA is not doing good in the industry: 96.51% of the companies in the same industry are doing better.
RKDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.27
ROIC/WACCN/A
WACC9.25%
RKDA Yearly LT Debt VS Equity VS FCFRKDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 4.60 indicates that RKDA has no problem at all paying its short term obligations.
The Current ratio of RKDA (4.60) is better than 94.19% of its industry peers.
RKDA has a Quick Ratio of 4.24. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
RKDA has a better Quick ratio (4.24) than 95.35% of its industry peers.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.24
RKDA Yearly Current Assets VS Current LiabilitesRKDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.87% over the past year.
Looking at the last year, RKDA shows a decrease in Revenue. The Revenue has decreased by -3.10% in the last year.
RKDA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.56% yearly.
EPS 1Y (TTM)77.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.06%
Revenue 1Y (TTM)-3.1%
Revenue growth 3Y-12.77%
Revenue growth 5Y29.56%
Sales Q2Q%-3.76%

3.2 Future

RKDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.25% yearly.
The Revenue is expected to grow by 6.27% on average over the next years.
EPS Next Y91.83%
EPS Next 2Y38.61%
EPS Next 3Y23.25%
EPS Next 5YN/A
Revenue Next Year-16.75%
Revenue Next 2Y2.19%
Revenue Next 3Y6.27%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RKDA Yearly Revenue VS EstimatesRKDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
RKDA Yearly EPS VS EstimatesRKDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RKDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RKDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RKDA Price Earnings VS Forward Price EarningsRKDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RKDA Per share dataRKDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

RKDA's earnings are expected to grow with 23.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.61%
EPS Next 3Y23.25%

More info and screens

0

5. Dividend

5.1 Amount

RKDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCADIA BIOSCIENCES INC

NASDAQ:RKDA (1/21/2025, 8:24:09 PM)

After market: 5.05 +0.1 (+2.02%)

4.95

-0.06 (-1.2%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners2.71%
Inst Owner Change0%
Ins Owners0.3%
Ins Owner Change0%
Market Cap6.73M
Analysts82.5
Price Target9.18 (85.45%)
Short Float %3.2%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.74%
Min EPS beat(2)-50.66%
Max EPS beat(2)-42.82%
EPS beat(4)2
Avg EPS beat(4)-16.96%
Min EPS beat(4)-50.66%
Max EPS beat(4)21.21%
EPS beat(8)5
Avg EPS beat(8)-1.54%
EPS beat(12)9
Avg EPS beat(12)9.76%
EPS beat(16)13
Avg EPS beat(16)40.15%
Revenue beat(2)2
Avg Revenue beat(2)23.06%
Min Revenue beat(2)7.71%
Max Revenue beat(2)38.42%
Revenue beat(4)3
Avg Revenue beat(4)3.7%
Min Revenue beat(4)-34.45%
Max Revenue beat(4)38.42%
Revenue beat(8)5
Avg Revenue beat(8)-6.76%
Revenue beat(12)6
Avg Revenue beat(12)-7.15%
Revenue beat(16)8
Avg Revenue beat(16)22.21%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.74%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.73%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.35
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-4.7
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-8.51
FCFYN/A
OCF(TTM)-8.5
OCFYN/A
SpS3.68
BVpS7.56
TBVpS7.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.23%
ROE -56.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.96%
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-51.16%
ROE(3y)-76.39%
ROE(5y)-123.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.48%
GM growth 5Y-3.26%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.38%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.24
Altman-Z -25.27
F-Score3
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)37.51%
Cap/Depr(5y)249.2%
Cap/Sales(3y)5.23%
Cap/Sales(5y)34.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.06%
EPS Next Y91.83%
EPS Next 2Y38.61%
EPS Next 3Y23.25%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.1%
Revenue growth 3Y-12.77%
Revenue growth 5Y29.56%
Sales Q2Q%-3.76%
Revenue Next Year-16.75%
Revenue Next 2Y2.19%
Revenue Next 3Y6.27%
Revenue Next 5YN/A
EBIT growth 1Y41.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.61%
EBIT Next 3Y21.55%
EBIT Next 5YN/A
FCF growth 1Y37.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.75%
OCF growth 3YN/A
OCF growth 5YN/A